TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: change in functional outcomes (incontinence or erectile function)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Vestibular Vertigo Severity Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: muscle pannation angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: muscle fiber length
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Clinical relevance of molecular analyses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: LISA implant survival rate
Endpoint domain: Mortality/survival
Primary endpoint: ODI change between pre-operative assessment and 2 years follow-up
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Safety and tolerability parameters including change from baseline measures for vital signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and tolerability parameters including change from baseline for clinical laboratory tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and tolerability parameters including change from baseline in the collection of adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of errors during dissection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of patients with Primary Graft Dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Alzheimer's Disease Assessment Scale, cognitive subscale (ADAS-cog)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Number of Participants With Vaccine Antibody Titers at ≥ 8 Before and After Menactra Vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Serum Bactericidal Assay Baby Rabbit Complement (SBA BR) Geometric Mean Titers Before and Post Menactra Vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants With at Least a 4-fold Increase in Antibodies to Menactra Vaccine Antigens Post Vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Muscle strength (kg)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intra-hospital complications
Endpoint domain: Adverse events/effects
Primary endpoint: Per-operative complications
Endpoint domain: Adverse events/effects
Primary endpoint: plateletcrit (PCT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Platelet Distribution Width (PDW)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Changes in Gastrointestinal Symptom Rating Scale (GSRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Volumetric analysis of buccal contour
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EEG recording
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mean Improvement of Lower Extremity Spider Veins
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Radioactivity recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinically significant findings in physical examination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinically significant findings in vital signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IOP pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Antitumor Objective Response Rate (ORR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Serious Adverse Device Effect (SADE) free rate
Endpoint domain: Adverse events/effects
Primary endpoint: Threshold measurements of left ventricular capture control feature
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of Acute and Chronic Grade 3 or Greater Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Levels of Dihydrotestosterone (DHT) and Testosterone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Number of Completed Exit Interviews
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in blood ammonia levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Pressure gradient across the aortic valve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Maximum plasma glucose concentration (GLUmax, mmol/L)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Maximum plasma glucose excursion (ΔGLUmax, mmol/L)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time to GLUmax (Tmax, min)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Virologic response rate at year 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) of RO6874281
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Optimal Biological Dose (OBD) of RO6874281
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of gait pattern
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Xerosis score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Dexlansoprazole
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in trough Forced Expiratory Volume in one second (FEV1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Acceptability to Providers and Patients
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: hemodynamic data
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of methylated DNA markers for detection of cancer of the prostate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Proportion of patients ready to receive chemotherapy on Day 15
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Parental Role Satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of Participants Employed
Endpoint domain: Resource use
Endpoint subdomain: Societal/carer burden
Primary endpoint: Number of Participants in a Relationship
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Change in Osame's Motor Disability Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to administration of fibrinogen replacement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Worsening knee pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incident cartilage loss on MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Function loss
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: detection rate of preterm preeclampsia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: New or newly enlarging lesions/Gadolinium enhancing lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Systolic Blood Pressure Variation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Heart Rate Variation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Systolic Blood Pressure Variation in Elderly (>55y)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: High sensitivity-troponin T level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Symptoms of Menopause
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Compliance of this HRT Regimen
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: earlier time to discharge
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Proportion of patients completing at least one call with the Quitline
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Device and implant procedure-related bacteremia
Endpoint domain: Adverse events/effects
Primary endpoint: Skeletal Muscle Protein Synthesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Density of total length of small perfused vessels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Subjects with Valtech Cardinal Mitral Heart Valve Device Technical Success
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Subject's Mitral Valve Regurgitation (MR) Post-procedure as Compared to Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Amplitude values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Angular velocity values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hearing Aid Satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Western Ontario McMaster University Osteoarthritis Index
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Plasma antithrombin (AT) activity levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Typical GERD symptoms (frequency and severity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient's perspective of symptom control and impact on daily life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Area under the plasma concentration-time curve extrapolated to infinity (AUCinf) of milademetan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Partial pressure of Oxygen in arterial blood to fraction of inspired Oxygen (P/F ratio)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Concentration of P-selectin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrence of prolapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With SLE Responder Index (SRI) Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Participants Able to Pair & Apply a Patch Independently
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change from baseline dynamic maximal endurance at week 9
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline dynamic maximal strength at week 9
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Average 24-hour Pain Score
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Bacterial binding rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Intrabony defect measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Seroconversion rate for HPV 16 and 18
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cognitive mediation skills
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Patient self care
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Acetabular wear in mm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Loss of bone mineral density (BMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change From Baseline to Week 52 in 4-Item Composite Score of Niemann Pick Type C Severity Scale (NPC-SS) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Classified With Each Score on the Clinician Global Impression of Change (CGIC) at Week 52
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Clinic visit for heart failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Vessel-specific quantification of myocardial blood flow RFR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Testosterone (T) Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Adverse Events (Long-term Safety)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentages of Subjects Who Complete the 12-month Treatment Period or Discontinue Due to AE (Tolerability)
Endpoint domain: Adverse events/effects
Primary endpoint: Confirmed Renal Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: RR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Skeletal response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: prolonged ventilation
Endpoint domain: Adverse events/effects
Primary endpoint: reintubation
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in plasma levels of metabolites of the intestinal microbiome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of steroid requiring exacerbations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Lower limb extensor power
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time that a drug is present at the maximum concentration [Tmax]
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hematologic Improvement-Erythroid (HI-E) rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Time to nephrotoxicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Dorsiflexion strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: MRI and pacing system related Serious Adverse Device Effect (SADE) free rate
Endpoint domain: Adverse events/effects
Primary endpoint: pacing threshold rise (atrial and ventricular)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: P-wave sensing attenuation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: R-wave sensing attenuation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in satisfaction with care
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: change of best corrected visual acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: the probability of vitreous haemorrhage
Endpoint domain: Adverse events/effects
Primary endpoint: Immune response 21 days post vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportion of Subjects With Remission at Month 6
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration to achieve full enteral feeds
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Presence of focal myometrial contraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Impedance cardiography
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of addictions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hamstring and quadriceps muscle strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Response on ICU Stressful Experiences Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Visual analog scores (VAS) for pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perioperative opioid requirements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients who achieve eRVR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of delayed clinical or molecular adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Composite event of cerebro/cardiovascular death, nonfatal cerebral stroke, and nonfatal myocardial infarction
Endpoint domain: Mortality/survival
Primary endpoint: Shoulder/arm morbidity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Alpha or beta diversity of intestinal microbiota composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: levator hiatus area in cm2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 25(OH)D Plasma Concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of lymph nodes visualized (fluorescent and nonfluorescent)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Sensitivity of HCV RDTs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of HCV RDTs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Impairments in function, activity limitations, and participation restrictions
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Symptoms associated with lymphedema
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Grip strength (newton)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Latency of anticipatory eye movement (ms)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fasting Blood Glucose Level at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Vitreous hemorrhage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Mean Children's Depression Rating Scale (CDRS-R)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mental Health Inventory
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Axis I Structured Clinical Interview for DSM-IV (SCID)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in symptoms of psychological distress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Leicester Cough Questionnaire (LCQ) total score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of patients without progression at 1 year
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients without treatment discontinuation due to adverse event during the first year
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of concomitant TGA and proven RCVS
Endpoint domain: Adverse events/effects
Primary endpoint: Intratidal ventilation heterogeneity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Intracranial injuries on CT scan
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Post concussion symptoms
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of Participants With HIV-1 RNA Viral Load <50 Copies/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Percentage of Participants With HIV-1 RNA Viral Load <50 Copies/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: AUCt,ss for BI 187004
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCt,ss for metformin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax,ss for BI 187004
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax,ss for metformin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Surgical Site Infections
Endpoint domain: Adverse events/effects
Primary endpoint: Minutes of N3 Stage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Minutes of REM Stage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participant's Desire to Continue Using VR After the Study Ends
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Participant's Satisfaction With the VR-BA Treatment
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: How Well Can Participants Tolerate the VR-BA Treatment?
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Minor allele frequency (MAF) in ctDNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Chest x-ray utilization
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Antibiotic utilization
Endpoint domain: Resource use
Endpoint subdomain: Other resource use